GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bicycle Therapeutics PLC (NAS:BCYC) » Definitions » Selling, General, & Admin. Expense

Bicycle Therapeutics (Bicycle Therapeutics) Selling, General, & Admin. Expense : $62.25 Mil (TTM As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Bicycle Therapeutics Selling, General, & Admin. Expense?

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Bicycle Therapeutics's selling, general, & admin. expense for the three months ended in Mar. 2024 was $16.45 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Mar. 2024 was $62.25 Mil.


Bicycle Therapeutics Selling, General, & Admin. Expense Historical Data

The historical data trend for Bicycle Therapeutics's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bicycle Therapeutics Selling, General, & Admin. Expense Chart

Bicycle Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Selling, General, & Admin. Expense
Get a 7-Day Free Trial 14.56 29.20 32.44 48.95 59.83

Bicycle Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Selling, General, & Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.04 15.18 15.57 15.05 16.45

Competitive Comparison of Bicycle Therapeutics's Selling, General, & Admin. Expense

For the Biotechnology subindustry, Bicycle Therapeutics's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bicycle Therapeutics's Selling, General, & Admin. Expense Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bicycle Therapeutics's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where Bicycle Therapeutics's Selling, General, & Admin. Expense falls into.



Bicycle Therapeutics Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $62.25 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bicycle Therapeutics  (NAS:BCYC) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


Bicycle Therapeutics Selling, General, & Admin. Expense Related Terms

Thank you for viewing the detailed overview of Bicycle Therapeutics's Selling, General, & Admin. Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Bicycle Therapeutics (Bicycle Therapeutics) Business Description

Industry
Traded in Other Exchanges
Address
Granta Park, Great Abington, Blocks A and B, Portway Building, Cambridge, GBR, CB21 6GS
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops which stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical need. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.
Executives
Nigel Crockett officer: Chief Business Officer C/O BICYCLE THERAPEUTICS PLC, B900, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Travis Alvin Thompson officer: Chief Accounting Officer C/O BICYCLE THERAPEUTICS PLC, BLOCKS A & B, PORTWAY BUILDING, CAMBRIDGE X0 CB21 6GS
Alistair Milnes officer: Chief Operating Officer C/O BICYCLE THERAPEUTICS PLC, B900, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Kevin Lee director, officer: Chief Executive Officer C/O BICYCLE THERAPEUTICS LIMITED, B900 BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB223AT
Nicholas Keen officer: Chief Scientific Officer C/O BICYCLE THEAPEUTICS LIMITED, B900 BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Michael Skynner officer: Chief Operating Officer C/O BICYCLE THERAPEUTICS LIMITED, B900 BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB223AT
Alethia Young officer: Chief Financial Officer C/O GRAPHITE BIO, INC., 201 HASKINS WAY, SUITE 210, SOUTH SAN FRANCISCO CA 94080
Lee Kalowski officer: President and CFO C/O TOKAI PHARMACEUTICALS, INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Santiago Arroyo officer: Chief Development Officer C/O MOMENTA PHARMACEUTICALS, INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Dominic Smethurst officer: Chief Medical Officer C/O BICYCLE THERAPEUTICS PLC, B900, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Pierre Legault director P.O. BOX 1028, C/O STONE MANAGEMENT LLC, BERWYNE PA 19312
Kate Bingham director 1365 MAIN STREET, WALTHAM MA 02451
Jose-carlos Gutierrez-ramos director C/O MOMENTA PHARMACEUTICALS, INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Plc Glaxosmithkline director, 10 percent owner 980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0 TW8 9GS
Veronica Gh Jordan director C/O ALBANY MOLECULAR RESEARCH, INC., 26 CORPORATE CIRCLE, ALBANY NY 12212-5098

Bicycle Therapeutics (Bicycle Therapeutics) Headlines

From GuruFocus

Ridgeback Capital Investments L.P.'s Top 5 Buys of the 4th Quarter

By GuruFocus Research GuruFocus Editor 02-17-2023